Actively Recruiting
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Led by Incyte Corporation · Updated on 2026-04-17
290
Participants Needed
13
Research Sites
255 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
CONDITIONS
Official Title
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Life expectancy greater than 6 months
- Willingness to undergo pretreatment and regular bone marrow biopsies and aspirates as appropriate
- Documentation from a qualified laboratory of CALR exon-9 mutation
- Diagnosis of myelofibrosis or essential thrombocythemia as defined in the protocol
You will not qualify if you...
- Presence of any blood cancer other than essential thrombocythemia, primary myelofibrosis, or post-essential thrombocythemia myelofibrosis
- Major bleeding or thrombosis within 3 months before study enrollment
- Laboratory values exceeding protocol-defined thresholds
- Prior or planned allogenic or autologous stem-cell transplantation
- Active invasive cancer within the past 2 years
- History of significant or uncontrolled heart disease
- Active or chronic hepatitis B, active hepatitis C, or known HIV infection
- Prior chemotherapy, immunomodulatory, immunosuppressive, biological, endocrine, targeted therapy, antibody, or hypomethylating agent within 5 half-lives or 28 days before first dose, except ruxolitinib for certain groups
- Treatment with G-CSF, GM-CSF, or TPO-R agonists within 4 weeks before first dose
- Other protocol-defined inclusion or exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
City of Hope Medical Center
Duarte, California, United States, 91010
Actively Recruiting
2
Stanford Cancer Institute
Palo Alto, California, United States, 94304
Actively Recruiting
3
University of Miami Health System
Miami, Florida, United States, 33136
Actively Recruiting
4
The University of Kansas Cancer Center
Westwood, Kansas, United States, 66205
Actively Recruiting
5
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
Actively Recruiting
6
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
7
Washington University School of Medicine
St Louis, Missouri, United States, 63108
Actively Recruiting
8
Icahn School of Medicine At Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
9
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
10
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States, 27157
Actively Recruiting
11
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
12
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
13
Md Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
I
Incyte Corporation Call Center (US)
CONTACT
I
Incyte Corporation Call Center (ex-US)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here